Lymphoma Action is delighted at the news that NHS England have agreed a deal to make CAR T-cell therapy available on the NHS for people with relapsed or refractory large cell lymphomas, such as diffuse large B-cell lymphoma (DLBCL).
This ground-breaking type of treatment offers new hope to people with very limited treatment options.
We recently reported on the draft decision not to recommend this treatment, and submitted a response stressing the potential that CAR T-cell therapy offers to people with lymphoma.
Over the next few months, CAR T-cell therapy will be made available at a limited number of centres able to offer the expertise in delivering this treatment.
Lymphoma Action Chief Executive Ropinder Gill commented: 'This is really good news for people affected by this type of lymphoma. By reaching this agreement patients and their families who will have had to face limited treatment options now have a hope for the future.'